Anishiya Abrol > Hogan Lovells US LLP > Washington DC, United States > Lawyer Profile
Hogan Lovells US LLP Offices
![Hogan Lovells US LLP company logo](https://www.legal500.com/wp-content/uploads/sites/13/2022/05/2116.jpg?v=1653324150)
COLUMBIA SQUARE
555 THIRTEENTH STREET, NW
WASHINGTON DC 20004
DISTRICT OF COLUMBIA
United States
- Firm Profile
- Go to...
Anishiya Abrol
![Anishiya Abrol photo](https://www.legal500.com/wp-content/uploads/sites/13/2023/07/52253_1216340.jpg)
Work Department
Intellectual Property
Position
Counsel
Career
Anishiya Abrol supports companies in their development and commercialization of cutting-edge medical therapies and tools. She advises on and negotiates a variety of strategic transactions from collaborations to in-licensing and out-licensing to maximize intellectual property assets, and then assists the company in implementing and integrating the new assets.
Anishiya has been seconded to multiple life sciences companies. She knows the issues facing in-house counsel and works closely with members of the firm’s Regulatory and Privacy Practice groups to provide integrated and practical advice.
Anishiya’s practice encompasses the full life sciences life cycle, from the discovery in the lab to dispensing to a patient. She has an undergraduate science degree, and her curious nature draws her towards early stage research and development transactions and activities, including clinical trial agreements, material transfer agreements, contract research organization (CRO) agreements, core lab agreements, sponsored research, grants, and technology transfers, both domestically and internationally. Recognizing though that a therapy’s primary value lies in the hands of patients, she assists commercialization efforts with support on distribution agreements, specialty pharmacy agreements, co-promotion agreements, authorized generic agreements, out-licensing arrangements, and other similar commercial activities.
Languages
English
Memberships
Chair, Wills for Heroes Program, Virginia Bar Association (2008-2013)
Member, American Health Law Association
Member, Virginia Bar Association
Education
J.D., George Mason University School of Law, magna cum laude, 2004
B.A. Biology, University of Virginia, 1997
B.A. History, University of Virginia, 1997
Lawyer Rankings
United States > Healthcare > Life sciences
(Next Generation Partners)Hogan Lovells US LLP fields a deep litigation bench with expertise in the life sciences, strengthened by the October 2023 arrivals from Dechert LLP of patent litigators Howard Levine in Washington DC and Jennifer Swan in Silicon Valley, both of whom have experience in Hatch-Waxman disputes. On the non-contentious front, the practice supports major players in the pharmaceutical sector with their patent protection strategies, and is also noted for its work navigating the FDA approvals process. Leadership of the overarching practice is split between Philadelphia-based Steve Abrams, who handles IPOs and M&As in the sector, and Washington DC’s Lynn Mehler, who guides drug and biologics developers through the FDA approvals process; FDA approvals are also the key area of focus for Randy Prebula, also based in the capital. In Denver, Jodi Scott advises medical device manufacturers on MDRs and FDA inspections, while Washington’s David Fox tackles Hatch-Waxman litigation as it relates to generic drug production. Product liability litigation is the domain of Baltimore’s Lauren Colton, who represents clients facing MDLs and class actions, while Cullen Taylor and Anishiya Abrol, based in Virginia and Washington respectively, as supporting clients with the protection of their drug and medical devices patent portfolios and licensing transactions. Houston’s Andrew Strong is well versed in assisting early stage companies with growth strategies, financing and mergers.
Lawyer Rankings
- Life sciences United States > Healthcare
- Next Generation Partners United States > Healthcare > Life sciences
Top Tier Firm Rankings
- Transport > Aviation and air travel: litigation and regulation
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Industry focus > Education
- Government > Government relations
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Healthcare > Life sciences
- Antitrust > Merger control
- Transport > Rail and road: litigation and regulation
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
- International trade > Trade remedies and trade policy
Firm Rankings
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Antitrust > Cartel
- International trade > CFIUS
- International trade > Customs, export controls and economic sanctions
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Energy > Energy regulation: oil and gas
- Environment > Environment: regulatory
- Government > Government contracts
- Healthcare > Health insurers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Healthcare > Service providers
- Tax > US taxes: non-contentious
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Energy > Energy litigation: oil and gas
- Energy > Energy regulation: electric power
- Environment > Environment: litigation
- Finance > Fintech
- Labor and employment > Immigration
- Dispute resolution > International litigation
- Tax > International tax
- Antitrust > Merger control
- Finance > Restructuring (including bankruptcy): corporate
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
- Antitrust > Civil litigation/class actions: defense
- Finance > Structured finance: derivatives and structured products
- Investment fund formation and management > Private equity funds (including venture capital)
- Finance > Financial services regulation